GlassScriptPhysician profile
Farheen Yousuf
NPI 1912108366
$5,851.63
in general payments reported to CMS, 2019-2025
31 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,703 · 2020: $708 · 2021: $1,075 · 2022: $1,721 · 2023: $409 · 2024: $132 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $594 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $594.09 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,126.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $560.07 | 2019-2023 | Tradjenta, Jardiance |
| Novo Nordisk INC | $525.33 | 2019-2023 | Ozempic, Rybelsus |
| Amgen INC. | $501.52 | 2019-2025 | Evenity, Prolia, Tepezza |
| Sanofi-Aventis U.S. LLC | $467.38 | 2019-2023 | |
| Amneal Pharmaceuticals LLC | $364.40 | 2019-2023 | Unithroid |
| Radius Health, INC. | $350.65 | 2019-2023 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $305.02 | 2019-2023 | Farxiga |
| Abbvie INC. | $252.83 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $154.70 | 2021-2022 | |
| Abbott Laboratories | $135.35 | 2021-2025 | Freestyle Insulinx, Freestyle Libre 3, Proclaim |
| Mannkind Corporation | $132.94 | 2019-2022 | |
| Amarin Pharma, INC. | $120.18 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $115.21 | 2019-2022 | |
| Ibsa Pharma INC. | $101.71 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vistapharm, INC. | $80.47 | 2021 | |
| Merck Sharp & Dohme LLC | $76.98 | 2019-2021 | |
| Grt US Holding, INC. | $67.81 | 2022 | |
| Nevro Corp. | $51.14 | 2022 | |
| Medtronic, INC. | $48.60 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $46.85 | 2019-2022 | |
| Corcept Therapeutics | $42.85 | 2021 | |
| Valeritas, INC. | $39.04 | 2019 | |
| Insulet Corporation | $38.62 | 2019-2021 | |
| Shire North American Group INC | $37.40 | 2019 | |
| Althera Pharmaceuticals LLC | $25.36 | 2021 | |
| Dexcom, INC. | $21.78 | 2024 | Dexcom G6 Transmitter |
| Opko Pharmaceuticals, LLC | $17.16 | 2021 | |
| Intuity Medical INC | $16.82 | 2022 | |
| Vivus LLC | $14.46 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farheen Yousuf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.